LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at…
A study published this week has found that when cancer cells are stressed, they produce a certain protein that helps the cancer…
For decades, health policymakers have relied on a survey tool to get early awareness of emerging public health threats before…
BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (“M&As”) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing…
In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and…
BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets…
A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered…
LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is…
ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance. The company’s core…
HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.…